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Abstract
Background: The basal ganglia (BG) are thought to play an important role in the control of eye movements.
Accordingly, the broad variety of subtle oculomotor alterations that has been described in Parkinson’s disease (PD)
are generally attributed to the dysfunction of the BG dopaminergic system. However, the present study suggest
that dopamine substitution is much less effective in improving oculomotor performance than it is in restoring
skeletomotor abilities.
Methods: We investigated reactive, visually guided saccades (RS), smooth pursuit eye movements (SPEM), and
rapidly left-right alternating voluntary gaze shifts (AVGS) by video-oculography in 34 PD patients receiving oral
dopaminergic medication (PD-DA), 14 patients with deep brain stimulation of the nucleus subthalamicus (DBS-
STN), and 23 control subjects (CTL);In addition, we performed a thorough review of recent literature according
therapeuthic effects on oculomotor performance in PD by switching deep brain stimulation off and on in the PD-
DBS patients, we achieved swift changes between their therapeutic states without the delays of dopamine
withdrawal. In addition, participants underwent neuropsychological testing.
Results: Patients exhibited the well known deficits such as increased saccade latency, reduced SPEM gain, and
reduced frequency and amplitude of AVGS. Across patients none of the investigated oculomotor parameters
correlated with UPDRS III whereas there was a negative correlation between SPEM gain and susceptibility to
interference (Stroop score). Of the observed deficiencies, DBS-STN slightly improved AVGS frequency but neither
AVGS amplitude nor SPEM or RS performance.
Conclusions: We conclude that the impairment of SPEM in PD results from a cortical, conceivably non-
dopaminergic dysfunction, whereas patients’ difficulty to rapidly execute AVGS might be related to their BG
dysfunction.
Keywords: Deep brain stimulation, Parkinson?’?s Disease, Oculomotor function, Neurophysiology, Eye movement,
Neurodegeneration
Background
A broad variety of oculomotor alterations have been
described in Parkinson’s disease (PD) such as an
increased latency of visually guided reactive saccades,
reduced saccadic gain, impaired smooth pursuit and dif-
ficulties to inhibit unwarranted reactions [1]. Existing
literature mainly focuses on different aspects of saccadic
dysfunction and basal ganglia pathology without arriving
at a generally accepted view. The substantia nigra and
related brainstem areas are suggested to be crucially
involved in various types of saccadic eye movements by
mediating a dopamine-related descending input from
frontal cortical areas to the superior colliculus [2], but
are also thought to play a role in inhibiting inappropri-
ate saccades [3]. To better understand the emergence of
oculomotor alterations in PD, the effects of therapy on
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stimulation of the subthalamic nucleus, STN-DBS) have
been repeatedly examined. Some studies show no effect
of dopaminergic medication [4], whereas other studies
do show effects on latency, gain or amplitude of sac-
cades (e.g. [5]). In general, dopaminergic treatment is
supposed to be of little effect on ocular motor deficits
in PD [6], in contrast to its benefit for limb motor func-
tion. Regarding the effects of STN-DBS on saccadic
f u n c t i o n ,t h e r ee x i s to n l yaf e ws t u d i e s ,s of a r .M o s to f
these report a reduction of the latency of visually eli-
cited reactive saccades (RS) [2] as well as an increase in
gain [7,8], whereas another study found no effect on
latency and gain of RS [9] but an improvement of the
amplitude of memory guided saccades [8]. Finally, a sin-
gle case report suggests that saccadic intrusions in
patients can be reduced by STN-DBS [10]. Since STN-
DBS is generally accepted to be highly effective in redu-
cing the levodopa sensitive parkinsonian motor symp-
toms [11], these observations suggest that oculomotor
deficits in PD might to a considerable part be caused by
a dysfunction of non-dopaminergic systems.
There is ample evidence that PD is a multisystem dis-
order with involvement of several brain regions and
neurotransmitter pathways other than dopamine [12].
Hence the cause of numerous clinicopathological corre-
lates of PD-related deficits such as cognitive dysfunction,
dementia, depression, and behavioural or emotional dys-
function have to be searched outside the nigrostriatal
system. Recently, these neuropsychological and psychia-
tric changes in PD have received considerable attention.
They are supposed to arise either as a part of the disease
itself but also as a collateral result of STN-DBS [13]. If
non-dopaminergic deficits cause indeed some of the eye
movement alterations in PD, it might be possible to
demonstrate a correlation between such non-motor
symptoms and oculomotor impairment in PD.
Since a number of methodological concerns compli-
cate the interpretation and comparison of studies that
examine the impact of dopaminergic therapy (different
testing procedures, failure to counterbalance ‘on’ and
‘off’ order of testing, different dopaminergic medication
and withdrawal regimes [14]), we chose to study PD
patients with STN-DBS in the “on” and “off” condition
and medication “on”, but also PD patients with exclu-
sively oral dopaminergic medication. Patients’ eye move-
ment were recorded by video-oculography (VOG) and
analysed in relation to their demographic, clinical and
neuropsychological data.
Methods
Patients and controls
Fourteen patients with the diagnosis of PD receiving
STN-DBS (PD-DBS), 34 PD patients with exclusively
oral dopaminergic medication (PD-DA), and 23 age
matched controls (CTL) free of any neurological disease
were examined by VOG. The relevant demographic
details are listed in Table 1. All subjects gave their
informed consent, and the study was approved by the
local ethics committee.
The diagnosis of PD was made according to the UK
Parkinson’s Disease Society (UKPDS) Brain Bank criteria
[16]. All patients were assessed and diagnosed by a
board-certified neurologist specialized in movement dis-
orders. The Unified Parkinson’s Disease Rating Scale
( U P D R S )P a r tI I I( m o t o ra s s e s s m e n t )w a sp e r f o r m e di n
all PD-DBS and 23 PD-DA patients. The PD-DBS
patients were examined with medication “on” in the
conditions stimulation “on” (PD-DBS-on) and stimula-
tion “off” (PD-DBS-off).
Neuropsychological assessment
In all PD-DBS patients and in 10 of the PD-DA patients,
neuropsychological tests were conducted which included
a recognition vocabulary test of general intelligence
("Wortschatztest”, WST) and assessments of dementia
(Parkinson Neuropsychometric Dementia Assessment,
PANDA), depression (German version of the Geriatric
depression scale, GDS) and susceptibility to interference
(Stroop colour-word-test/"Farbworttest”,F W T ) .A sa
score of susceptibility to interferences pointing to frontal
failure, FWT3-2 was obtained from the difference
between the times required for subtests 3 and 2 of FWT
(in s).. Learning in decision making was evaluated with
a PC version of the IOWA gambling task (IGT) In DBS,
all tests except IGT were only performed during “on";
the IGT was also performed 30-45 min after suspending
stimulation.
Eye movement recording and analysis
The investigation took place in an optically and acousti-
cally shielded room. Subjects were seated, with their
heads stabilised by a chin rest, in a comfortable chair at
the centre of a hemicylindrical screen (radius, 160 cm).
The screen carried a horizontal array of red light emit-
ting diodes (LEDs; spaced 5°, up to 20° right and left;
invisible when not lit). Visually guided reactive saccades
(RS) were elicited by randomly lighting one of these
LEDs as a target in such way that target steps of 5, 10,
20, and 40° resulted. Self-paced rapidly left-right alter-
nating voluntary gaze shifts (AVGS) were obtained by
asking subjects to saccade back and forth as frequently
as possible for 30 s between two permanently lit red
LEDs spaced 20° horizontally. Smooth pursuit eye move-
ments (SPEM) in horizontal and vertical direction were
elicited by sinusoidal movements of a red laser spot
across the screen (horizontal amplitude ± 20°, vertical ±
15°, frequencies 0.125 and 0.375 Hz). The movements of
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I
®, SR Research Ltd., Osgoode, ON, Canada) at a sam-
pling rate of 250 Hz and an effective angular resolution
of about 0.05°. The restriction to horizontal saccades
was necessary to limit the period of time the severely
handicapped DBS patients would spend in the “off” con-
dition. According to [17], after suspending stimulation
the beneficial effect of DBS-STN on akinetic, rigid and
tremor symptoms decreases to reach a plateau after 30
min without any further worsening within two more
hours. Therefore, recording in the “off"-state originally
was intended to start 45 min after stopping stimulation;
however, depending on the severity of the patients’
symptoms in the “off"-state, recording had to be started
between 30 and 45 minutes after stopping stimulation,
as otherwise some patients would have not been able to
complete the examination. The order of recording dur-
ing “off” and “on” was randomised across patients; “on"-
recordings following an “off"-state were commenced 45
min after resumption of stimulation.
For analysis, the following parameters were extracted
from the left and the right eye recordings, respectively:
(1) SPEM gain (fundamental component of SPEM velo-
city/target velocity), (2) peak velocity of RS of 20° ampli-
tude (by interpolation along the “main sequence”), (3)
latency and (4) gain of RS aimed at targets of 20° retinal
eccentricity (amplitude of primary saccade/20°), (5)
number N30 and (6) gain G(N30) of AVGS executed
within 30 s where G(N30) was calculated from the lar-
gest saccade of each gaze shift.
Statistical analysis
None of the groups exhibited systematic differences
between the right and the left eye. Therefore, analyses
are based on averages of the monocular parameters. To
detect an effect of group, all oculomotor parameters
were subjected to a Kruskal-Wallis analysis of variance
(ANOVA) with those of DBS being taken from the “on”
state (PD-DBS-on) as the best therapy equivalent of PD-
DA. Suspected differences between these groups were
analysed with the Mann-Whitney U test with probabil-
ities being Bonferroni corrected according to the num-
ber of comparisons. PD-DBS-off was compared to PD-
DBS-on by a matched pairs Wilcoxon tests. To check
for neuropsychological differences between PD-DA and
DBS-on, the Mann-Whitney U test was used. For possi-
ble correlations between oculomotor, clinical, and neu-
ropsychological data, Spearman’s rank correlation
coefficient was used. A threshold of p <0 . 0 5w a s
adopted for all statistical inferences.
Results
Clinical data
Most DBS patients continued to receive a regular adju-
vant dopaminergic medication after surgery. However, its
dose could be considerably reduced as compared to the
presurgical level (average levodopa equivalent, 509 mg/
day) At the time of eye movement recording, their aver-
a g eU P D R Sp a r tI I Is c o r ei m p r o v e df r o m3 8 . 8d u r i n g
“off” to 29 during “on” (p < 0.001) And so did the sub-
score for rapid alternating hand movements (2.7 versus
2.1, p < 0.018).. PD-DA patients had received L-DOPA
equivalents of 917 mg/day [15] and reached an average
UPDRS score of 20.3 (2.0 for the hand movement sub-
score). For details of medication and UPDRS see Table 1.
Neuropsychological assessment
There were no significant differences in the applied tests
between PD-DBS-on and PD-DA except for a lower
GDS score in the PD-DBS-on patients (PD-DA: mean
4.5 ± 2.7; PD-DBS-on: 3.3 ± 2.8; p = 0.021). Gambling
score IGT did not differ between “on” (mean 4.2 ± SD
21) and “off” (3.4 ± SD 30) conditions in PD-DBS
patients.
Eye movement data
ANOVA indicated a significant effect of group (CTL,
PD-DA, PD-DBS-on) on most of the investigated eye
Table 1 Demographic data, medication (levodopa equivalent) and clinical scores.
CTL PD-DA PD-DBS
on off
Number of subjects
total (male, female)
23 (18m, 5f) 34 (21m, 13f) 14 ( 9m, 5f)
Age (yrs)
mean (± SD), range
61.7 (± 7.1), 49-76 63.0 (± 11.7), 36-81 64.2 (± 7.1), 50-74
Disease duration (yrs)
mean (± SD), range
6.9 (± 4.4), 1-16 10.5 (± 4.0), 4-19
Levodopa equivalent medication (mg/day)
mean (± SD), range
917 (± 578), 200-2650 509 (± 348), 0-1250
UPDRS motor scale
mean (± SD), range
20.3 (± 13.0), 2-56 29, 0 (± 16.3), 5-62 38.8 (± 14.3), 16-64
Equivalent doses are given according to Tomlinson et al., 2010 [15]
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ward pursuit gain, saccade gain and saccade peak velo-
city. These effects were due to significant differences
between both PD-DA and PD-DBS-on on the one hand
and CTL on the other hand, whereas PD-DA and PD-
DBS-on did not differ between each other. Specifically,
SPEM gain and the number and gain of voluntary sac-
cades produced within 30 s (N30) was markedly reduced
in patients (Figure 1), whereas saccade latency (only PD-
DA) increased. No parameter changed significantly
when stimulation was switched off in DBS patients
except for N30 which exhibited a just significant
decrease (p = 0.046).
Correlation analyses
To detect possible correlations between patients’ oculo-
motor results, neuropsychological performance, demo-
graphic data and clinical scores, we pooled the data of
groups PD-DA and PD-DBS-on as their oculomotor and
neuropsychological variables were statistically indistin-
guishable (except for GDS). UPDRS part III correlated
with none of the parameters and scores considered; also
a comparison of the subscore for rapid alternating hand
movements with the frequency (N30) and gain (G(N30))
of rapidly alternating gaze shifts (AVGS) revealed no
correlation. Likewisedisease duration (except for a signif-
icant correlation with FWT3-2, cf. below) was uncorre-
lated to any of the parameters considered.. Also, no
correlation existed in the DBS subgroup between the
changes of UPDRS III and of its alternating hand move-
ments subscore resulting from STN-DBS and the conco-
mitant changes of eye movement parameters. FWT3-2
correlated negatively with low frequency (0.125 Hz) hor-
izontal (r = -0.46, p = 0.025) and downward (r = -0.46,
p = 0.028) SPEM gain and positively with disease
duration (r = 0.51, p = 0.014), while PANDA correlated
only with 0.125 Hz downward SPEM gain (r = 0.48, p =
0.017). Otherwise, age was an important factor in both
PD and CTL; high frequency (0.375 Hz) SPEM gain
decreased with age in PD (r < -0.34, p <0 . 0 2f o rh o r i -
zontal and downward, trend for upward; Figure 2b, c) as
did N30 (r = -0.40 p = 0.011), whereas RS latency
increased with age (r = 0.36, p = 0.012; Figure 2a). Qua-
litatively similar trends held for the CTL group (signifi-
cant for downward SPEM, r = -0.42 p = 0.046) and
latency r = 0.57, p = 0.002). In the case of saccade
latency, the regression lines of latency on age had vir-
tually identical slopes in PD and CTL, with the former
being shifted upward by about 60 ms (Figure 1a).
Discussion
In this study we investigated whether an accurate assess-
ment of oculomotor changes in PD patients - subdivided
in a group with oral dopaminergic medication and a
group of STN-DBS patients in the DBS “on” and “off”
condition with additional oral dopaminergic medication
- may allow a conclusion as to the pathomechanism of
oculomotor dysfunction in PD. With regard to oculomo-
tor function, we observed a reduced SPEM gain (typi-
cally caused by the release of predictive saccades, cf.
Figure 1 in [18]), increased latency of RS (in PD-DA
only) and a decreased number and gain of AVGS in all
patient groups in comparison to controls. These results
are in general agreement with the literature on oculo-
motor dysfunction in PD (i.e. [1]). However, none of the
investigated oculomotor parameters exhibited significant
differences between patients treated with dopamine only
(group PD-DA) and those receiving STN-DBS (group
PD-DBS-on). In DBS patients, the only effect of stimula-
tion withdrawal was a just significant reduction of N30
Table 2 Oculomotor results.
Smooth pursuit gain Saccades
0.125 Hz 0.375 Hz Visually guided reactive Alternating voluntary
horiz. up down horiz. up down L (ms) G20 Vpk (°/s) N30 G(N30)
CTL 0.98 0.94 0.89 0.92 0.89 0.57 245 0.91 419 62 0.96
0.91-1.02 0.75-0.98 0.61-1.02 0.55-0.98 0.46-1.00 0.26-0.77 205-323 0.87-0.98 312-473 50-79 0.94-0.99
PD-DA 0.91* 0.87 0.87 0.77* 0.54* 0.48 296* 0.88 424 48* 0.89*
0.60-.99 0.57-1.01 0.55-0.99 0.19-0.94 0.16-0.91 0.24-0.82 214-502 0.76-0.97 330-502 21-68 0.75-0.98
PD-DBS-on 0.89* 0.71* 0.77 0.74* 0.45* 0.42 268 0.88 390 28* 0.87*
0.47-.98 0.51-.95 0.53-0.97 0.31-0.95 0.11-0.83 0.22-0.79 223-424 0.78-0.93 288-501 23-70 0.81-0.93
PD-DBS-off 0.83 0.66 0.71 0.66 0.38 0.31 288 0.88 389 23
+ 0.82*
0.58-1.00 0.39-0.97 0.52-1.03 0.24-0.97 0.17-0.84 0.14-0.86 226-446 0.68-1.01 284-494 13-69 0.74-1.03
Median values with 5%-95%-ranges. L, latency; G20, gain of reactive saccades (RS) aimed at targets of 20° eccentricity; Vpk, peak velocity of RS with 20°
amplitude (obtained by interpolation along the main sequence); N30 and G(N30), number and gain rapidly alternating back and forth gaze shifts during 30s-
epoch (AVGS). *, significant differences with respect to CTL (Kruskal-Wallis-ANOVA of groups CTL, PD-DA and PD-DBS-on followed by Mann-Whitney group
comparisons, Bonferroni corrected for multiple testing; all cases p < 0.005) except saccade latency of PD-DA vs. CTL (p < 0.01); note that there were no significant
differences between PD-DA and PD-DBS-on.
+, significant difference (p < 0.05) between PD-DBS-on and PD-DBS-off (Wilcoxon matched pairs); note that PD-DBS-
off was not compared to CTL or PD-DA to avoid repeated measurements
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not differ.
STN-DBS has been reported to significantly reduce
the latency of visually triggered saccades [2,7,8], and to
increase their gain [7,8]. Similar to the present study,
Rivaud-Péchoux et al. observed an only non-significant
shortening of latency by STN-DBS but a reduction of
errors in an antisaccades task. A convincing mechanistic
explanation for the observed improvements does not
seem to exist, so far. Since STN neurones are thought
to excite crossed nigro-collicular cells, it is difficult to
understand how a supposedly elevated STN activity in
PD could facilitate (instead of prevent) the release of
inappropriate saccades by the colliculus observed in
many studies [4,6] or how a reduction of STN overactiv-
ity by DBS could lead to the reduction of inappropriate
saccades noted in other studies [10]. Sauleau et al. [7]
invoke an altered control of the interaction between
STN and substantia nigra pars reticulata (SNpr) in
advanced PD which would be restored to normal via
improved functioning of the parieto-collicular pathway.
Temel et al. [19] suggest that the reduction of STN
activity by DBS enhances the facilitation of the colliculus
by interacting with the cortico-basal-collicular pathway.
Yugeta et al. [8] invoke the more recent finding that PD
pathology may be linked to the occurrence of abnormal
oscillatory b-activity in STN. Similar to skeleto-motor
performance [20], desynchronisation of this activity by
STN-DBS would also be beneficial for oculomotor beha-
viour although its differential effect on reactive and
unsolicited saccades remains to be explained.
Why do our measurements of saccadic latency not
reproduce the beneficial effect of STN-DBS reported by
others? With regard to latency and saccadic gain, the
majority of our STN-DBS patients appear to have been
too close to normal to exhibit any sizeable effect of STN-
DBS. Moreover, the tendency for longer saccade latencies
in PD as compared to CTL may in part have resulted
from their dopaminergic medication that had been
received two hours before eye movement recording [5].
We are unaware of studies that would have examined
the effect of STN-DBS on the SPEM gain. The lack of a
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Figure 1 Sample records of self-paced gaze shifts alternating as rapidly as possible between two permanently lit targets subtending
20° (AVGS). a, DBS-off patient; b, control.
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Figure 2 Oculomotor performance as a function of age. Blue filled circles, control subjects (CTL); green diamonds, patients with only
dopamine therapy (PD-DA) or with additional STN-DBS (PD-DBS-on, green diamonds framed by black squares); red triangles, DBS patients during
stimulation off (PD-DBS-off). a, latency of reactive saccades; arrows link “on"- and “off"-data of those 4 Patients who exhibited latencies outside
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patients suggests that the stimulation does not improve
the inhibitory control of unwarranted saccades during
pursuit (a main cause of SPEM gain reduction,
[18,21-26]). Experimental evidence for an amelioration
of inhibitory control from previous studies by STN-DBS
is mixed, at best. STN-DBS was found ineffective at
reducing antisaccade errors [8,9], but reportedly
diminishes the frequency of premature saccades during
a memory saccade task [8].
As a further paradigm which has not been studied
during STN-DBS, we have examined the ability to
rapidly saccade back and forth between two fixed tar-
gets. This paradigm was the only one to reveal a signifi-
cant but small improvement under STN-DBS. This
result is in line with the notion of the basal ganglia
being particularly important for voluntary, endogenous
saccades [3] in PD. In summary, our data suggest that
STN-DBS can increase the frequency of voluntary sac-
cades but does not improve SPEM gain in PD.
In contrast to the investigated eye movement para-
meters, the patients’ skeletomotor system (UPDRS III
scores) clearly improved with STN-DBS. The beneficial
effect of STN-DBS on motor function is well established
[11]. Nevertheless, if the observed eye movement altera-
tions in PD resulted from a dysfunction of mainly dopa-
mine-mediated mechanisms that can be relieved by
STN-DBS, there should exist a correlation between
STN-DBS-related improvement in UPDRS III and eye
movement performance. We observed no such correla-
tion, in particular when comparing the only eye move-
ment parameter improving with DBS-STN (N30) to a
skeletomotor analogue (UPDRS III subscore for rapid
alternating hand movements). However, also authors
who noted a SPEM improvement with dopamine ago-
nists point out that this effect is much smaller than the
concurrent UPDRS III improvement [22].
Also studies addressing the effect of dopamine on eye
movements have produced ambiguous results (i.e.
[4-6,23]). Some of these studies warrant methodological
concerns such as different medication and withdrawal
regimes (for a review, [14]). Moreover, the long half-
value period of the ubiquitously applied dopamine ago-
nists makes it difficult to examine patients in a true
medication-off state since the medication-free time has
to be limited for ethical reasons and because it is
unclear whether there is a direct link between the
plasma level of medication and possible influences on
oculomotor function.
Compared with skeleto-motor function, there may be
not an as clear a link between pathologic STN oscilla-
tions and eye movement alterations as these oscillations
mainly affect dorsal STN and less so the ventral, eye
movement related STN [25] Therefore, the effect of
STN-DBS on eye movement alterations may be limited.
Taken all together, the above considerations are in line
with growing evidence that pathologies outside the
dopaminergic nigrostriatal pathway may also be respon-
sible for oculomotor deficits in PD (i.e. [26]). In view of
t h eo c c u r r e n c eo ff r o n t a ll o b ep a t h o l o g yi nP D[ 1 8 ] ,a n
impact of non-dopaminergic alterations in frontal corti-
cal areas on eye movement control in PD is conceivable
[27]. In this regard Rieger et al. [28] have found the
frontal eye field itself to be hypoactive when performing
horizontal voluntary saccades in an fMRI study. This
study [28] as well as data showing a statistically signifi-
cant correlation between the impairment of smooth pur-
suit and premature saccades in a delayed saccade task in
PD [21] strongly support for the assumption of a top-
down frontostriatal pathomechanism of saccadic dys-
function in PD..
Conclusions
A v a i l a b l el i t e r a t u r eo f f e r sam i x e dp i c t u r ec o n c e r n i n g
the effects of therapy on eye movement control in PD,
be it dopaminergic medication or high frequency deep
brain stimulation. Some studies show no effect of dopa-
minergic medication [4], whereas others report effects
on latency, gain or amplitude of saccades (i.e. [5]). In
general, dopaminergic treatment has been found to be
of little effect on the ocular motor deficits in PD [6].
STN-DBS has been reported to significantly reduce the
latency of visually triggered saccades [2,7,8], and to
increase their gain [7,8]. If eye movement alterations in
PD resulted from a dysfunction of dopamine-mediated
mechanisms exclusively, motor performance in general
should correlate with eye movement performance both
in terms of disease progression and therapeutical
response. The lack of such correlation in our data sup-
ports the idea of a mainly non-dopaminergic top-down
frontostriatal pathomechanism of oculomotor dysfunc-
tion in PD.
Author details
1Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081
Ulm, Germany.
2Department of Neurology, Section Neurophysiology,
University of Ulm, Ulm, Germany.
Authors’ contributions
EH P, RJ, DL, JH, ACL, WB and JK participated in the design and coordination
of the study, helped in the acquisition of data, contributed substantially to
the interpretation of data, drafted the manuscript and read and finally
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 September 2011 Accepted: 29 February 2012
Published: 29 February 2012
Pinkhardt et al. BMC Neurology 2012, 12:5
http://www.biomedcentral.com/1471-2377/12/5
Page 7 of 8References
1. Pinkhardt EH, Kassubek J: Ocular motor abnormalities in Parkinsonian
syndromes. Parkinsonism Relat Disord 2011, 17:223-230.
2. Temel Y, Tan S, Vlamings R, Sesia T, Lim LW, Lardeux S, Visser-Vandewalle V,
Baunez C: Cognitive and limbic effects of deep brain stimulation in
preclinical studies. Front Biosci 2009, 14:1891-1901.
3. Hikosaka O, Takikawa Y, Kawagoe R: Role of the basal ganglia in the
control of purposive saccadic eye movements. Physiol Rev 2000,
80:953-978.
4. Crevits L, Versijpt J, Hanse M, De Ridder K: Antisaccadic effects of a
dopamine agonist as add-on therapy in advanced Parkinson’s patients.
Neuropsychobiology 2000, 42:202-206.
5. Hood AJ, Amador SC, Cain AE, Briand KA, Al-Refai AH, Schiess MC,
Sereno AB: Levodopa slows prosaccades and improves antisaccades: an
eye movement study in Parkinson’s disease. J Neurol Neurosurg Psychiatry
2007, 78:565-570.
6. Rascol O, Clanet M, Montastruc JL, Simonetta M, Soulier-Esteve MJ,
Doyon B, Rascol A: Abnormal ocular movements in Parkinson’s disease.
Evidence for involvement of dopaminergic systems. Brain 1989, 112(Pt
5):1193-1214.
7. Sauleau P, Pollak P, Krack P, Courjon JH, Vighetto A, Benabid AL, Pelisson D,
Tilikete C: Subthalamic stimulation improves orienting gaze movements
in Parkinson’s disease. Clin Neurophysiol 2008, 119:1857-1863.
8. Yugeta A, Terao Y, Fukuda H, Hikosaka O, Yokochi F, Okiyama R,
Taniguchi M, Takahashi H, Hamada I, Hanajima R, Ugawa Y: Effects of STN
stimulation on the initiation and inhibition of saccade in Parkinson
disease. Neurology 2010, 74:743-748.
9. Rivaud-Pechoux S, Vermersch AI, Gaymard B, Ploner CJ, Bejjani BP,
Damier P, Demeret S, Agid Y, Pierrot-Deseilligny C: Improvement of
memory guided saccades in parkinsonian patients by high frequency
subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2000,
68:381-384.
10. Wark HA, Garell PC, Walker AL, Basso MA: A case report on fixation
instability in Parkinson’s disease with bilateral deep brain stimulation
implants. J Neurol Neurosurg Psychiatry 2008, 79:443-447.
11. Benabid AL, Chabardes S, Mitrofanis J, Pollak P: Deep brain stimulation of
the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet
Neurol 2009, 8:67-81.
12. Lang AE, Obeso JA: Challenges in Parkinson’s disease: restoration of the
nigrostriatal dopamine system is not enough. Lancet Neurol 2004,
3:309-316.
13. Antonini A, Isaias IU, Rodolfi G, Landi A, Natuzzi F, Siri C, Pezzoli G: A 5-year
prospective assessment of advanced Parkinson disease patients treated
with subcutaneous apomorphine infusion or deep brain stimulation.
J Neurol 2011, 4:579-585.
14. Harrison J, Henderson L, Kennard C: Abnormal refractoriness in patients
with Parkinson’s disease after brief withdrawal of levodopa treatment.
J Neurol Neurosurg Psychiatry 1995, 59:499-506.
15. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE: Systematic
review of levodopa dose equivalency reporting in Parkinson’s disease.
Mov Disord 2010, 25:2649-2653.
16. Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis
of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988,
51:745-752.
17. Lopiano L, Torre E, Benedetti F, Bergamasco B, Perozzo P, Pollo A,
Rizzone M, Tavella A, Lanotte M: Temporal changes in movement time
during the switch of the stimulators in Parkinson’s disease patients
treated by subthalamic nucleus stimulation. Eur Neurol 2003, 50:94-99.
18. Zgaljardic DJ, Borod JC, Foldi NS, Mattis PJ, Gordon MF, Feigin A,
Eidelberg D: An examination of executive dysfunction associated with
frontostriatal circuitry in Parkinson’s disease. J Clin Exp Neuropsychol 2006,
28:1127-1144.
19. Temel Y, Visser-Vandewalle V, Carpenter RH: Saccadometry: a novel clinical
tool for quantification of the motor effects of subthalamic nucleus
stimulation in Parkinson’s disease. Exp Neurol 2009, 216:481-489.
20. Kuhn AA, Kempf F, Brucke C, Gaynor Doyle L, Martinez-Torres I, Pogosyan A,
Trottenberg T, Kupsch A, Schneider GH, Hariz MI, et al: High-frequency
stimulation of the subthalamic nucleus suppresses oscillatory beta
activity in patients with Parkinson’s disease in parallel with
improvement in motor performance. J Neurosci 2008, 28:6165-6173.
21. Pinkhardt EH, Kassubek J, Sussmuth S, Ludolph AC, Becker W, Jurgens R:
Comparison of smooth pursuit eye movement deficits in multiple
system atrophy and Parkinson’s disease. J Neurol 2009, 256:1438-1446.
22. Bares M, Brazdil M, Kanovsky P, Jurak P, Daniel P, Kukleta M, Rektor I: The
effect of apomorphine administration on smooth pursuit ocular
movements in early Parkinsonian patients. Parkinsonism Relat Disord 2003,
9:139-144.
23. Nakamura T, Kanayama R, Sano R, Ohki M, Kimura Y, Aoyagi M, Koike Y:
Quantitative analysis of ocular movements in Parkinson’s disease. Acta
Otolaryngol Suppl 1991, 481:559-562.
24. Moschner C, Baloh RW: Age-related changes in visual tracking. J Gerontol
1994, 49:M235-M238.
25. Weinberger M, Mahant N, Hutchison WD, Lozano AM, Moro E, Hodaie M,
Lang AE, Dostrovsky JO: Beta oscillatory activity in the subthalamic
nucleus and its relation to dopaminergic response in Parkinson’s
disease. J Neurophysiol 2006, 96:3248-3256.
26. Mosimann UP, Muri RM, Burn DJ, Felblinger J, O’Brien JT, McKeith IG:
Saccadic eye movement changes in Parkinson’s disease dementia and
dementia with Lewy bodies. Brain 2005, 128:1267-1276.
27. Chan PL, Nutt JG, Holford NH: Modeling the short- and long-duration
responses to exogenous levodopa and to endogenous levodopa
production in Parkinson’s disease. J Pharmacokinet Pharmacodyn 2004,
31:243-268.
28. Rieger JW, Kim A, Argyelan M, Farber M, Glazman S, Liebeskind M, Meyer T,
Bodis-Wollner I: Cortical functional anatomy of voluntary saccades in
Parkinson disease. Clin EEG Neurosci 2008, 39:169-174.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/12/5/prepub
doi:10.1186/1471-2377-12-5
Cite this article as: Pinkhardt et al.: Eye movement impairments in
Parkinson’s disease: possible role of extradopaminergic mechanisms.
BMC Neurology 2012 12:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pinkhardt et al. BMC Neurology 2012, 12:5
http://www.biomedcentral.com/1471-2377/12/5
Page 8 of 8